Next month’s U.S. election results are once again triggering concerns over tighter drug pricing regulations should Democrats take control of Congress. On Tuesday, October 11, 2016, the $7.6 billion iShares Nasdaq Biotechnology exchange-traded fund fell 3.8 percent—its biggest decline since the Brexit. This morning, Stock-Callers.com takes a look at Immunomedics Inc., ImmunoGen Inc., INSYS Therapeutics Inc., and Jazz Pharmaceuticals PLC to see how they have fared at the closing bell on Friday, October 14, 2016.
New Jersey headquartered Immunomedics Inc.’s stock dropped 4.58 percent, finishing last Friday’s session at $2.29. A total volume of 1.42 million shares was traded, which was above their three months average volume of 1.38 million shares. The company’s shares are trading below their 200-day moving average by 18.27 percent. Additionally, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have a Relative Strength Index (RSI) of 28.01.
On October 06th, 2016, research firm Jefferies resumed its ‘Buy’ rating on the company’s stock.
On October 12th, 2016, Immunomedics announced that it has closed on a previously disclosed underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock, with gross proceeds of $30 million. Each share of common stock and its accompanying warrant was priced at $3.00. Immunomedics intends to use the proceeds from the offering primarily in continuing support of clinical and regulatory activities for IMMU-132, including submission of a NDA to FDA for accelerated approval in metastatic triple-negative breast cancer, and for working capital and general corporate purposes.
On Friday, shares in Waltham, Massachusetts headquartered ImmunoGen Inc. ended the session 5.81 percent, lower at $2.27. The stock recorded a trading volume of 1.97 million shares, which was above its three months average volume of 1.20 million shares. The company’s shares are trading below their 50-day moving average by 19.91 oercent. Moreover, shares of ImmunoGen, which develops targeted anticancer therapeutics, have an RSI of 26.93.
On September 29th, 2016, ImmunoGen announced the completion of a strategic review of its operations. As a result of this initiative, the company will reduce its workforce by 17 percent and seek to partner its non-core B-cell lymphoma programs, creating a stronger organization focused on delivering innovative ADC therapies that meaningfully improve the lives of cancer patients.
Chandler, Arizona headquartered INSYS Therapeutics Inc.’s stock fell 6.36 percent, to close the day at $11.05, with a total trading volume of 719,353 shares. Shares of the company, which develops and commercializes supportive care products, are trading 24.52 percent below their 50-day moving average. The stock has an RSI of 31.48.
On September 22nd, 2016, research firm RBC Capital Markets reiterated its ‘Outperform’ rating on the company’s stock with a decrease of the target price from $32 a share to $26 a share.
On October 13th, 2016, Insys Therapeutics announced that its preliminary estimated revenues from Subsys® for Q3 2016 will be in the range of $54 million to $55 million. The company believes it will be cash-flow positive at this level of sales and will be able to meet its overall objectives of new product development and future growth. Estimated revenues for the quarter reflect a decline in prescriptions as the company continues to believe that the ongoing and heightened publicity surrounding the national opioid epidemic and continuing governmental and regulatory scrutiny of the company and the transmucosal immediate release fentanyl (TIRF) class has resulted in a sensitivity by some healthcare providers to prescribe and dispense TIRF medications.
Shares in Ireland headquartered Jazz Pharmaceuticals PLC recorded a trading volume of 302,168 shares, and ended Friday’s session at $118.34, down 2.30 percent. The stock is trading below its 50-day moving average by 8.05 percent. Shares of the company, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the U.S., Europe, and internationally, have an RSI of 35.56.
On October 03rd, 2016, Jazz Pharma announced the initiation of a rolling submission of a New Drug Application (NDA) to the U.S. FDA on September 30th, 2016, seeking marketing approval of Vyxeos™, an investigational agent for the treatment of acute myeloid leukemia (AML). The company expects to complete the submission of the NDA by early 2017, and will request a priority review. Vyxeos was granted Breakthrough Therapy Designation in May 2016 for the treatment of adults with therapy-related AML or AML with myelodysplasia-related changes.
To view the full press release, click here.